← All candidates
41 insider filings on record.
41 filings on record.
JANXJanux Therapeutics, Inc.
NasdaqGM · Healthcare · $1.05B
$16.25
-1.19% · Sep 16
41 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 11 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$1.05B
Float
42.5M
70% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
43.6
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
36 more transactions on Pro →Context
Wall St
$40.56 avg target
+149.7% vs today · 16 analysts
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
3 of 4 quarters beat
Q1 '26−$0.39 act+$0.13
Q4 '25−$0.51 act+$0.13
Q3 '25−$0.39 act+$0.22
Q2 '25−$0.55 act−$0.08
Coverage
Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should KnowZacks · 05-28Here's Why You Should Add JANX Stock to Your Portfolio NowZacks · 05-26Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue EstimatesZacks · 05-07How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44%Zacks · 05-07
The file stays open
41 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice